title: Complete lymph node dissection for sentinel node-positive melanoma: assessment of practice patterns in the United States.
abstract: BACKGROUND
  Currently, complete lymph node dissection (CLND) is recommended after identification of a metastatic lymph node by sentinel lymph node biopsy (SLNB). Guidelines suggest that CLND should be performed as a separate procedure, and a sufficient number of nodes should be examined. Our objective was to examine the utilization, timing, and adequacy of CLND for melanoma in the United States.
  
  
  METHODS
  From the National Cancer Data Base, patients diagnosed with stage I to III melanoma during 2004-2005 were identified. Multiple logistic regression was used to assess factors associated with CLND utilization, timing (separate operation from SLNB), and adequacy (examination of > or = 10 nodes).
  
  
  RESULTS
  Of the 44,548 patients identified, 47.5% were pathologic stage IA, 23.8% stage IB, 14.1% stage II, and 14.6% stage III. Of the 17% (2942 of 17,524) with nodal metastases on SLNB, only 50% underwent a CLND. Patients were significantly less likely to undergo a CLND after SLNB if > 75 years old or had lower extremity melanomas. Of the patients who underwent a CLND, only 42% underwent the CLND at a separate procedure after the SLNB. Of those who underwent a CLND, 69.2% had > or = 10 nodes examined. Patients were significantly less likely to have > or = 10 nodes examined if they were > 75 years old or had lower extremity melanomas. Patients treated at NCCN/NCI-designated centers were significantly more likely to undergo nodal evaluation in concordance with established guidelines.
  
  
  CONCLUSIONS
  Only half of patients with sentinel node-positive melanoma underwent CLND. Quality surveillance measures are needed to monitor, standardize, and improve the care of patients with malignant melanoma.
authors.affiliation: Cancer Programs, American College Surgeons, Chicago, IL, USA. k-bilimoria@northwestern.edu
authors.forename: Karl Y
authors.initials: KY
authors.lastname: Bilimoria
authors.forename: Charles M
authors.initials: CM
authors.lastname: Balch
authors.forename: David J
authors.initials: DJ
authors.lastname: Bentrem
authors.forename: Mark S
authors.initials: MS
authors.lastname: Talamonti
authors.forename: Clifford Y
authors.initials: CY
authors.lastname: Ko
authors.forename: Julie R
authors.initials: JR
authors.lastname: Lange
authors.forename: David P
authors.initials: DP
authors.lastname: Winchester
authors.forename: Jeffrey D
authors.initials: JD
authors.lastname: Wayne
mesh_terms: D000368:Aged; D002983:Clinical Competence; D005260:Female; D006801:Humans; D008197:Lymph Node Excision / Q000379:methods*; D008297:Male; D008545:Melanoma / Q000473:pathology*; D008875:Middle Aged; D009367:Neoplasm Staging; D011364:Professional Practice; D021701:Sentinel Lymph Node Biopsy; D012878:Skin Neoplasms / Q000473:pathology*; D014481:United States